摘要
AIM： To study the dynamic changes of hepatits B virus （HBV） DNA in serum and peripheral blood mononuclear cells （PBMCs） of patients after lamivudine therapy. METHODS： A total of 72 patients with chronic HBV infection were included in this study. All patients were confirmed to have the following conditions： above 16 years of age, elevated serum alanine amonotransferase （ALT）, positive hepatitis B e antigen （HBeAg）, positive HBV DNA in serum and PBMCs, negative antibodies against HAV, HCV, HDV, HEV. Other possible causes of chronic liver damages, such as drugs, alcohol and autoimmune diseases were excluded. Seventy-two cases were randomly divided into lamivudine treatment group （n = 42） and control group （n = 30）. HBV DNA was detected both in serum and in PBMCs by fluorescence quantitative polymerase chain reaction （PCR）, during and after lamivudine treatment. RESULTS： In the treatment group, HBV DNA became negative both in serum and in PBMC, of, 38 and 25 out of 42 cases respectively during the 48 wk oflamivudine treatment, the negative rate was 90.5% and 59.5% respectively. In the control group, the negative rate was 23.3% and 16.7% respectively. It was statistically significant at 12, 24 and 48 wk as compared with the control group （P 〈 0.005）. The average conversion period of HBV DNA was 6 wk （2-8 wk） in serum and 16 wk （8-24 wk） in PBMC.CONCLUSION： Lamivudine has remarkable effects on HBV replication both in serum and The inhibitory effect on HBV DNA in PBMCs than that in serum inhibitory in PBMCs. is weaker
瞄准：在浆液和外部血学习肝炎 B (HBV ) DNA 的动态变化在 lamivudine 以后的病人的单音的原子房间(PBMC ) 治疗。方法：有长期的 HBV 感染的 72 个病人的一个总数在这研究被包括。所有病人被证实有下列条件：超过 16 岁，提高了浆液丙氨酸 aminotransferase (中高音) ，积极肝炎 B e 抗原(HBeAg ) ，在浆液和 PBMC 的积极 HBV DNA，对 HAV 的否定抗体， HCV， HDV， HEV。长期的肝损坏的另外的可能的原因酒精和自体免疫的疾病例如药，被排除。72 个盒子随机被划分成 lamivudine 治疗组(n = 42 ) 并且控制组(n = 30 ) 。HBV DNA 被荧光在浆液并且在 PBMC 检测量的聚合酶链反应(PCR ) ，在期间并且在 lamivudine 治疗以后。结果：在治疗组， HBV DNA 在 lamivudine 治疗的 48 wk 期间分别地从 42 个盒子在浆液并且在 PBMC 变得否定， 38 和 25，否定的率分别地是 90.5% 和 59.5% 。在控制组，否定的率分别地是 23.3% 和 16.7% 。它作为与控制组(P<0.005 ) 相比在 12， 24 和 48 wk 是统计上重要的。HBV DNA 的平均变换时期在 PBMC 在浆液和 16 wk (8-24 wk ) 是 6 wk (2-8 wk ) 。结论：Lamivudine 在浆液并且在 PBMC 在 HBV 复制上有显著禁止的效果。在 PBMC 的 HBV DNA 上的禁止的效果在浆液是比那弱的。
基金
Supported by the Innovation Foundation of Wuhan University,No.301270054
